Prasinezumab Shows Potential Effect of Delaying Motor Progression in Parkinson Disease
September 18th 2021Despite not meeting the primary end point, those in the early-start group showed reduced change from baseline in MDS-UPDRS-III scores compared with the delayed-start group at both weeks 52 and 104.
Efficacy, Safety, and Tolerability of Apomorphine Sublingual Film: William Ondo, MD
September 17th 2021The director of the Movements Disorders Clinic at Houston Methodist Neurological Institute discussed data presented at the International Parkinson and Movement Disorders Society Virtual Congress 2021.
How APPs and Organizations Can Address the Neurologist Shortage: Jennifer Majersik, MD, MS
September 16th 2021The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.
Applying Artificial Intelligence and Neuroimaging Into Clinical Care: Michael Dwyer, PhD
September 16th 2021The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided a realistic perspective of when and how AI will be incorporated into the wider medical system.
The Critical Nature of Patient-Focused MS Care: Patricia Bobryk, MHS, PT, MSCS, ATP
September 15th 2021With the field of multiple sclerosis care focusing on the importance of patient-reported outcomes and shared decision-making, the physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists offered commentary.